Total Payments
$934,438
2024 Payments
$112,401
Companies
36
Transactions
437
Medicare Patients
339
Medicare Billing
$71,672
Payment Breakdown by Category
Consulting$701,060 (75.0%)
Other$94,710 (10.1%)
Research$85,587 (9.2%)
Travel$44,311 (4.7%)
Food & Beverage$8,731 (0.9%)
Education$39.54 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $701,060 | 159 | 75.0% |
| Unspecified | $85,587 | 43 | 9.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $71,395 | 20 | 7.6% |
| Travel and Lodging | $44,311 | 88 | 4.7% |
| Honoraria | $15,098 | 4 | 1.6% |
| Food and Beverage | $8,731 | 113 | 0.9% |
| Compensation for serving as faculty or as a speaker for a medical education program | $5,668 | 3 | 0.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,550 | 3 | 0.3% |
| Education | $39.54 | 4 | 0.0% |
Payments by Type
General
$848,851
394 transactions
Research
$85,587
43 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| TAIHO ONCOLOGY, INC. | $150,087 | 32 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $120,201 | 58 | $0 (2023) |
| BioCryst Pharmaceuticals, Inc. | $101,625 | 6 | $0 (2024) |
| Celgene Corporation | $74,901 | 46 | $0 (2024) |
| PFIZER INC. | $61,406 | 30 | $0 (2022) |
| Astellas Pharma Global Development | $56,534 | 23 | $0 (2024) |
| ABBVIE INC. | $51,584 | 58 | $0 (2024) |
| Chiesi USA, Inc. | $40,890 | 10 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $29,603 | 11 | $0 (2021) |
| Daiichi Sankyo Inc. | $28,544 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $112,401 | 43 | TAIHO ONCOLOGY, INC. ($21,915) |
| 2023 | $127,666 | 47 | BioCryst Pharmaceuticals, Inc. ($32,275) |
| 2022 | $108,994 | 43 | BioCryst Pharmaceuticals, Inc. ($30,100) |
| 2021 | $122,143 | 45 | Taiho Oncology, Inc. ($34,741) |
| 2020 | $148,055 | 53 | Novartis Pharmaceuticals Corporation ($31,555) |
| 2019 | $132,083 | 102 | Taiho Oncology, Inc. ($30,850) |
| 2018 | $93,930 | 58 | Novartis Pharmaceuticals Corporation ($20,374) |
| 2017 | $89,165 | 46 | Novartis Pharmaceuticals Corporation ($28,142) |
All Payment Transactions
437 individual payment records from CMS Open Payments — Page 1 of 18
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | E.R. Squibb & Sons, L.L.C. | REBLOZYL (Biological) | Consulting Fee | Cash or cash equivalent | $1,384.00 | General |
| Category: Hematology | ||||||
| 12/19/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Consulting Fee | Cash or cash equivalent | $2,340.00 | General |
| Category: Oncology | ||||||
| 12/18/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Consulting Fee | Cash or cash equivalent | $9,918.12 | General |
| Category: Genetically Defined Disease | ||||||
| 12/10/2024 | BeiGene USA, Inc. | — | Travel and Lodging | In-kind items and services | $562.10 | General |
| 12/08/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Oncology | ||||||
| 12/08/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $130.00 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $2,610.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 12/05/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 12/05/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $4.23 | General |
| Category: Genetically Defined Disease | ||||||
| 12/04/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Travel and Lodging | Cash or cash equivalent | $360.65 | General |
| Category: Genetically Defined Disease | ||||||
| 11/20/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $1,350.00 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome • Category: ONCOLOGY | ||||||
| 11/20/2024 | Agios Pharmaceuticals, Inc. | PYRUKYND (Drug) | Food and Beverage | In-kind items and services | $77.55 | General |
| Category: Genetically Defined Disease | ||||||
| 11/07/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 10/30/2024 | ABBVIE INC. | VENCLEXTA (Drug) | — | Cash or cash equivalent | $725.00 | Research |
| Study: Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) • Category: ONCOLOGY | ||||||
| 10/11/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Consulting Fee | Cash or cash equivalent | $14,820.00 | General |
| Category: Oncology | ||||||
| 10/10/2024 | Chiesi USA, Inc. | FERRIPROX (Drug) | Consulting Fee | Cash or cash equivalent | $1,740.00 | General |
| Category: TREAT IRON OVERLOAD FROM THALASSEMIA, SICKLE CELL OR ANOTHER ANEMIA | ||||||
| 10/08/2024 | TAIHO ONCOLOGY, INC. | INQOVI (Drug) | Consulting Fee | Cash or cash equivalent | $4,680.00 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Kyowa Kirin, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,355.00 | General |
| 09/03/2024 | E.R. Squibb & Sons, L.L.C. | Revlimid (Drug) | Consulting Fee | Cash or cash equivalent | $1,695.40 | General |
| Category: Hematology | ||||||
| 09/03/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
| 08/16/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $6,412.50 | General |
| 08/16/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $520.45 | General |
| 08/16/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $65.15 | General |
| 08/08/2024 | Karyopharm Therapeutics Inc. | XPOVIO (Drug) | Consulting Fee | Cash or cash equivalent | $4,890.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $36,316 | 11 |
| AML CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $7,920 | 7 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $7,704 | 2 |
| A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) (ACE-536-MDS-001) | Celgene Corporation | $5,880 | 2 |
| Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs) | F. Hoffmann-La Roche AG | $3,872 | 1 |
| Clinical outcomes in patients with higher-risk myelodysplastic syndromes (HR-MDS) receiving hypomethylating agents (HMAs) | F. Hoffmann-La Roche AG | $3,872 | 1 |
| M15-954 | AbbVie Inc. | $3,375 | 1 |
| ((OBU) Sabatolimab )_MBG-AB -114226_RWE | Novartis Pharmaceuticals Corporation | $2,980 | 1 |
| A retrospective, observational cohort study using an electronic medical records database of patients diagnosed with relapsed or refractory RR FLT3 Acute Myeloid Leukemia AML | Astellas Pharma Global Development | $2,632 | 1 |
| A Phase 1, Open-label, Dose Finding Study of CC-90009, a Novel Cereblon E3 Ligase Modulating Drug, in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (CC-90009-AML-001) | Celgene Corporation | $2,079 | 1 |
| ACE-536-MDS-001 - A Study of Luspatercept (ACE-536) to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MEDALIST) | Celgene Corporation | $1,409 | 1 |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome | ABBVIE INC. | $1,350 | 1 |
| CMBG453B12201 | Novartis Pharmaceuticals Corporation | $1,084 | 1 |
| AG-221-AML-005 - Phase IIA AG-221-AML-005 (BMS Study Number: CA067-P12) | Celgene Corporation | $1,082 | 1 |
| HEOR Patient Outcomes | Celgene Corporation | $1,071 | 1 |
| A RETROSPECTIVE OBSERVATION COHORT STUDY USING AN ELECTRONIC MEDICAL RECORDS (EMR) DATABASE OF PATIENTS DIAGNOSED WITH RELAPSED OR REFRACTORY (R/R) FLT3+ ACUTE MYELOID LEUKEMIA (AML) | Astellas Pharma Global Development | $876.05 | 3 |
| Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) | ABBVIE INC. | $725.00 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH RESEARCH AGREEMENT | Novartis Pharmaceuticals Corporation | $614.00 | 1 |
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | Astellas Pharma Global Development | $340.00 | 1 |
| SINGLE-ARM, OPEN LABEL, PHASE II STUDY OF MBG453 (SABATOLIMAB) ADDED TO FDA APPROVED HYPOMETHYLATING AGENTS OF INVESTIGATOR'S CHOICE (IV/SC/ORAL) FOR PATIENTS WITH INTERMEDIATE, HIGH OR VERY HIGH RISK MYELODYSPLASTIC SYNDROME (MDS) AS PER IPSS-R CRITERIA (US MULTI-CENTER) (STIMULUS MDS-US) | Novartis Pharmaceuticals Corporation | $259.00 | 1 |
| A RETROSPECTIVE, OBSERVATIONAL COHORT STUDY USING AN ELECTRONIC MEDICAL RECORDS DATABASE OF PATIENTS DIAGNOSED WITH RELAPSED OR REFRACTORY (R/R) FLT3+ ACUTE MYELOID LEUKEMIA (AML) | Astellas Pharma Global Development | $66.66 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 48 | 103 | $43,185 | $9,364 |
| 2022 | 3 | 73 | 245 | $83,700 | $19,107 |
| 2021 | 4 | 117 | 304 | $99,045 | $23,194 |
| 2020 | 4 | 101 | 289 | $96,145 | $20,007 |
Total Patients
339
Total Services
941
Medicare Billing
$71,672
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 26 | 65 | $24,375 | $4,885 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 22 | 38 | $18,810 | $4,480 | 23.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 35 | 111 | $41,625 | $8,955 | 21.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 99 | $24,750 | $5,936 | 24.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 18 | 35 | $17,325 | $4,217 | 24.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 38 | 147 | $36,750 | $8,985 | 24.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 46 | 104 | $39,000 | $8,537 | 21.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 22 | 41 | $20,295 | $4,931 | 24.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 11 | 12 | $3,000 | $740.76 | 24.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 53 | 143 | $53,625 | $9,800 | 18.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 110 | $27,500 | $6,848 | 24.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 20 | $7,100 | $1,808 | 25.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 14 | 16 | $7,920 | $1,552 | 19.6% |
About Amer Zeidan
Amer Zeidan is a Hematology & Oncology healthcare provider based in New Haven, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2007. The National Provider Identifier (NPI) number assigned to this provider is 1083819528.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Amer Zeidan has received a total of $934,438 in payments from pharmaceutical and medical device companies, with $112,401 received in 2024. These payments were reported across 437 transactions from 36 companies. The most common payment nature is "Consulting Fee" ($701,060).
As a Medicare-enrolled provider, Zeidan has provided services to 339 Medicare beneficiaries, totaling 941 services with total Medicare billing of $71,672. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology, Hospitalist
- Location New Haven, CT
- Active Since 06/15/2007
- Last Updated 09/18/2014
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1083819528
Products in Payments
- INQOVI (Drug) $77,361
- XOSPATA (Drug) $41,279
- EXJADE (Drug) $36,316
- DAURISMO (Drug) $23,130
- VENCLEXTA (Drug) $22,592
- FERRIPROX (Drug) $21,750
- IBRANCE (Drug) $19,500
- ICLUSIG (Drug) $18,442
- LONSURF (Drug) $15,000
- Venclexta (Drug) $14,825
- PYRUKYND (Drug) $14,787
- Luspatercept (Drug) $13,657
- REBLOZYL (Biological) $13,610
- Xospata (Drug) $13,306
- TIBSOVO (Drug) $10,760
- RYDAPT (Drug) $10,450
- TAZVERIK (Drug) $8,400
- Tazverik (Drug) $8,400
- BOSULIF (Drug) $8,164
- Venclexta (Biological) $7,775
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in New Haven
Dr. Daniel Petrylak, M.d, M.D
Hematology & Oncology — Payments: $642,957
Hematology & Oncology $642,957
Cheryl Mensah, M.d, M.D
Hematology & Oncology — Payments: $236,631
Hematology & Oncology $236,631
Dr. Stacey Stein, Md, MD
Hematology & Oncology — Payments: $125,024
Hematology & Oncology $125,024
Walid Shaib, M.d, M.D
Hematology & Oncology — Payments: $89,344
Hematology & Oncology $89,344
Dr. Iris Isufi, M.d, M.D
Hematology & Oncology — Payments: $88,237
Hematology & Oncology $88,237
Dr. Shalin Kothari, Md, MD
Hematology & Oncology — Payments: $22,139
Hematology & Oncology $22,139